Porcine Reproductive & Respiratory Syndrome roadmap:
Vaccines
Roadmap for development of a candidate vaccine for PRRSV
Download PRRSV Vaccine Roadmap3
Rationally attenuated candidates
Dependencies
Development of an attenuated vaccine that doesn’t persist or is excreted
Research Question
- Replicating organisms are likely to give the most appropriate immune response but wild-type virus manipulates the host response. The aim is to reduce the virulence of the organism so that the vaccinated animal can mount a protective immune response
Research Gaps and Challenges
- The generation of GM organisms that are viable but lack virulence and non-protective immune-dominant antigens
- Identification of strains that give the greatest cross protection
- That vaccination prevents excretion of the organism – both the vaccine strain and wild type virus or any combination of the two that may have been generated
Solution Routes
- Monitoring the immune response following immunisation with the various candidates.
- Challenge experiments with the various vaccine candidates, including challenge with other strains
- Identity of cell lines that allow higher production of PRRSV
Dependencies
- The generation of stable genetically modified organisms
- Identity of virulence factors in PRRSV
- Identity of immunomodulators in PRRSV
Projects
What activities are planned or underway?
Generating antibodies broadly neutralising porcine reproductive and respiratory syndrome virus (PRRSV)
Planned Completion date 31/12/2025
Source Countries:
Denmark
Identification of interferon stimulated genes that control Toxoplasma in pig macrophages
Planned Completion date 01/03/2026
Source Countries:
United Kingdom